Zim Laboratories Limited has informed the Exchange about the Annual Report for the Financial Year 2024-25
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zim Laboratories has submitted its Annual Report for FY2024-25 to the exchanges, as required under SEBI Listing Regulations. The company reported Total Operating Income of ₹3,790 Mn, up 3.2% YoY, driven by strong export growth of 8.9% to ₹3,125 Mn. EBITDA grew 6.4% to ₹495 Mn with margins improving to 13.1%, though Profit After Tax declined 29.3% to ₹122 Mn due to higher finance costs (₹114 Mn vs ₹69 Mn) from increased borrowings of ₹1,122 Mn. The innovative products portfolio (NIP and OTF) showed strong momentum, with NIP revenue rising 82% to ₹437 Mn and OTF up 42% to ₹186 Mn. The company secured two EU Marketing Authorisations during the year and spent ₹365 Mn on CapEx to expand manufacturing capabilities.
Mixed signals for shareholders — topline growth and improving EBITDA margins are positive, but the sharp 29% drop in PAT and rising debt levels may concern investors. The strong growth in innovative products (NIP+OTF) and EU regulatory approvals signal future revenue potential, though execution risks remain in legacy markets facing geopolitical and payment issues.